PrEP Clears $1B a Quarter and Persistency Finally Has a Number, But the Revenue Raise Never Reaches EPS

Results vs. Consensus

Quality of Beat/Miss

• Revenue: Good, but not as clean as the headline. Total revenues beat consensus by roughly $430M–$450M, and about a third of that is neither recurring nor cash. Royalty, contract and other revenues came in at $176M against $27M a year ago, of which $156M was an accounting change lifting future estimated royalties tied to a prior intellectual property sale. Strip it out and product sales of $7,627M still clear the total-revenue consensus on their own, so the operating beat survives, but it is roughly two-thirds the advertised size. The base business also absorbed a Veklury line that came in around $78M below where the Street had it.
• Margins: Holding, not expanding. Non-GAAP product gross margin was 86.9%, flat to three basis points below the year-ago quarter and squarely in line with the ~87% full-year guide. Non-GAAP R&D fell 1% on lower oncology trial activity. The pressure point is non-GAAP SG&A at $1,521M, up 12% on Yeztugo promotion, which is running well ahead of the mid-single-digit full-year framework and is the single line most responsible for the revenue raise not reaching earnings.
• EPS: The underlying number is genuinely good and the reported number is genuinely irrelevant. Illustrative EPS of $2.27 grew about 13% against product sales growth of 8%, which is real operating leverage. Below that, the effective tax rate swung to negative 11.4% because the acquired IPR&D is not deductible; management put the ex-transaction rate at roughly 19%, consistent with the ~20% full-year framework. Nothing in the below-the-line detail flatters the operating result.

Segment Performance

HIV — the guide went up again, but the quality of the growth changed

HIV grew 12% to $5,693M, the franchise's strongest second-quarter growth in three years, and management raised full-year HIV growth to 9%–10% from the 8% set in May, which was itself raised from 6% in February. That is two upward revisions in two quarters on the single most important line in the company. The prevention business is doing the heavy lifting, and it deserves the headline.

"With a $4 billion annual run rate for our PrEP business and Biktarvy's continued strength, we are raising our full year HIV growth expectations to 9% to 10% year-over-year from prior guidance of 8% growth." — Daniel O'Day, Chairman & CEO

The composition is where a careful reader should slow down. Gilead's own release attributes the 12% to "higher average realized price and demand," in that order. Biktarvy's 7% was credited to higher realized price, favorable inventory dynamics and higher demand, again in that order. Descovy's PrEP growth of 60% was attributed first to price on channel mix. None of these is quantified, so it is not possible to separate volume from price from stocking with the disclosure provided.

Assessment: The raise is real and the prevention demand behind it is real, but this is a lower-quality 12% than the 10% we graded last quarter. Price and channel mix are finite levers and inventory build reverses. The pillar is intact and strengthening; we are simply no longer willing to treat the entire HIV growth rate as demand-led.

Prevention — the first billion-dollar quarter

Total PrEP sales exceeded $1B in a quarter for the first time, roughly doubling year over year against a U.S. PrEP market growing about 14%. Yeztugo contributed $232M and Descovy for PrEP roughly $801M. Gilead is compounding share on top of a market that is itself expanding at a double-digit rate, which is the rarer and more valuable of the two dynamics.

"In the PrEP switch market, Yeztugo is now the overall leader across oral and injectable options, an impressive achievement after only 4 full quarters of launch." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: A $4B annualized prevention business built in effectively four quarters of long-acting launch, sitting inside a market growing 14%, is the strongest asset Gilead has created in a decade. It is also the reason the HIV franchise is no longer a maturity story.

Yeztugo — the persistency question, answered

For two consecutive quarters we flagged second-dose persistency as the one number that would decide how large Yeztugo could become, and for two consecutive quarters management would say only that early data was encouraging. This quarter they put a figure on it.

"More than 70% of users so far have returned for reinjection at 6 months and extended their protection against HIV to a full year. We're very excited to see such a high level of persistency at a rate that we believe is well above available PrEP options." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Yeztugo sales of $232M grew 40% sequentially, and the full-year target of approximately $1B was reaffirmed rather than raised. With $397M booked in the first half, the second half needs roughly $600M, or about $300M a quarter against Q2's $232M.

Assessment: Above 70% at the six-month mark is a strong result for an injectable prevention product and materially de-risks the multi-year revenue curve. The mild oddity is that management raised the HIV franchise guide while leaving Yeztugo unchanged, which means the raise is being carried by Biktarvy and Descovy rather than by the launch asset. Either the $1B remains conservative, or the second-half ramp is expected to flatten. Neither was addressed.

Oncology — Trodelvy is working and the segment still grew 3%

Trodelvy grew 26% to $457M on demand across both triple-negative and pretreated HR-positive/HER2-negative metastatic breast cancer, and Gilead secured back-to-back FDA approvals in first-line metastatic TNBC across PD-L1 status during the quarter. Against that, cell therapy fell 14%, leaving total oncology up just 3%.

"With an addressable population almost double that of the second-line setting and a longer median duration of treatment, this represents an opportunity to further extend Trodelvy's reach and benefit for patients." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: The asset-level oncology story is genuinely good and the first-line label roughly doubles Trodelvy's addressable population. The segment-level story is that diversification is not yet visible in reported sales, because Kite is consuming Trodelvy's growth. That is a Kite problem rather than a Trodelvy problem, but investors underwriting diversification should be honest that it is still a pipeline fact rather than a revenue fact.

Cell therapy — the guide got worse, quietly

Cell therapy sales of $417M fell 14% year over year, with Yescarta down 12% and Tecartus down 24% on in-class and out-of-class competition. Sequentially the line was up 2%. The notable disclosure was the guidance change.

"And we now expect cell therapy to decline mid-teens percentage year-over-year." — Andrew Dickinson, Chief Financial Officer

That is a cut from the roughly 10% decline guided in February and reaffirmed in May, and it arrived inside the CFO's guidance walk without any accompanying explanation of what changed. Launch preparation for anito-cel is well advanced ahead of a December 23 PDUFA date, with contractual review and quality training under way at the majority of authorized treatment centers.

Assessment: Kite is eroding faster than the plan set six months ago, and the deterioration was delivered without commentary. The offset remains credible and now fully owned, but anito-cel contributes essentially nothing to 2026, so the mid-teens decline is a straight reduction to this year's earnings bridge with the recovery pushed into 2027.

Liver disease — the quiet compounder

Liver disease sales grew 10% to $877M with Livdelzi more than doubling to $167M, up 26% sequentially, and further contribution from hepatitis B products and Hepcludex, partly offset by lower HCV starts. Gilead received FDA accelerated approval for Hepcludex in chronic hepatitis delta during the quarter, the first and only approved U.S. treatment for that indication, and reported positive Phase 3 IDEAL results supporting a label expansion for Livdelzi in inadequately controlled PBC.

"Livdelzi continues to be the leading second-line PBC regimen, driving encouraging second quarter market growth as we move beyond first quarter seasonality." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: Livdelzi has now recovered from the Q1 sequential dip we told readers to ignore, and the IDEAL readout converts a label expansion from optionality into a probable 2027 event. Hepcludex is small by design. Liver remains the least-discussed and most consistently delivering part of the portfolio.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Confident and heavily forward-leaning, with the call organized around launches and catalysts rather than around the quarter's accounting. Management volunteered the persistency number without being asked, which is the posture of a team that likes its data. The counterpart to that confidence was selective silence: the largest negative disclosures of the quarter, a $1.75B intangible write-off and a cut to the cell therapy guide, were left out of the narrative entirely or slipped into a guidance walk without comment.

1. Prevention crosses $1B in a quarter

The defining operating fact of the quarter is that Gilead's PrEP business became a billion-dollar-a-quarter franchise, roughly doubling year over year while the underlying U.S. market grew about 14%. Two products drive it: Descovy for PrEP at roughly $801M, and Yeztugo at $232M in its fourth full quarter.

"Yeztugo has quickly become the leading long-acting PrEP option for new patient starts. Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time." — Daniel O'Day, Chairman & CEO

Management framed the two products as complementary rather than competing, with Yeztugo drawing switch business roughly evenly from injectable competition, Descovy and generics, while gradually building naive starts.

Assessment: A $4B annualized prevention business inside a market compounding at 14% changes what Gilead is. This is no longer a mature HIV treatment annuity with a prevention side project; prevention is now large enough to move the consolidated growth rate on its own.

2. Persistency above 70%, the number that was missing

Since the Q4 initiation we have flagged second-dose persistency as the swing variable in the Yeztugo model, on the logic that a twice-yearly injectable only compounds if patients come back. Management disclosed for the first time that more than 70% of users returned for reinjection at six months.

"More than 70% of users so far have returned for reinjection at 6 months and extended their protection against HIV to a full year." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Management also described a newly launched patient support program built with PrEP consumers, combining reminders, educational resources and an inbound and outbound nurse call center, intended to push the rate higher.

Assessment: This is the single most thesis-relevant disclosure of the quarter. A 70%-plus six-month return rate converts Yeztugo from a launch with an unknowable tail into a product with a modelable installed base. We are treating the multi-year Yeztugo curve as materially de-risked.

3. The HIV guide raise, and what is actually behind it

Full-year HIV growth moved to 9%–10% from 8%, the second raise in two quarters. Notably, the raise came without any change to the Yeztugo target of approximately $1B, so the incremental dollars are being attributed to Biktarvy and Descovy.

Both of those products were described in terms that lead with price. Gilead's release credits Biktarvy's 7% to "higher average realized price, favorable inventory dynamics and higher demand," and Descovy's 48% to "higher average realized price and demand." On the call, Descovy's 60% PrEP growth was attributed first to price favorability from channel mix.

Assessment: Raising the growth rate of a $20B-plus franchise twice in six months is a strong signal and we do not want to talk anyone out of it. But price and channel mix are not the same asset as demand, and the disclosure does not permit splitting them. The right posture is to credit the raise while marking the confidence interval around its durability wider than last quarter.

4. The ACA subsidy expiry hits the treatment market

The most substantive new negative on the call came in response to questioning rather than in prepared remarks. Management confirmed that the elimination of Affordable Care Act tax subsidies pushed patients out of exchange plans into uninsured or underinsured status, and that this measurably slowed HIV treatment market growth in the quarter.

"Sequentially, Biktarvy sales increased 12%, driven by typical seasonality, partially offset by lower demand due to market dynamics, including a greater-than-expected impact associated with changes in the Affordable Care Act." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Management expects the market to return to its normal 2%–3% annual growth rate, but offered neither a size for the Q2 impact nor a timeline for the recovery.

Assessment: "Greater-than-expected" is the operative phrase. The policy headwind we have carried as contained since February just came in worse than the company planned, and the recovery is an assertion rather than a forecast. This is the bear point that escalated this quarter.

5. Biktarvy's switch-market defense arrives this month

Biktarvy grew 7% to $3,772M and continued to gain year-over-year share in both naive and switch settings. The strategic development is BIC/LEN, a once-daily single-tablet regimen combining bictegravir with lenacapavir, which addresses the one structural leak in the franchise: patients who switch off Biktarvy have historically had to switch to a competitor.

"As previously shared, FDA has granted BIC/LEN priority review, and we continue to anticipate a decision by August 27." — Dietmar Berger, Chief Medical Officer

Behind it sits the once-weekly oral islatravir plus lenacapavir combination partnered with Merck, which met non-inferiority endpoints against both Biktarvy and physician's choice regimens in the Phase 3 ISLEND-1 and ISLEND-2 trials, with a potential 2027 launch.

Assessment: This is the mechanism by which the HIV annuity extends past Biktarvy's own exclusivity. A decision inside the next three weeks makes it the nearest catalyst in the name, though the 2026 revenue contribution from a late-August approval is immaterial.

6. The $1.75B write-off nobody discussed

Gilead recorded a $1,750M in-process R&D impairment in the quarter. The quarterly filing is explicit about what it is: following the June discontinuation of the Phase 3 EVOKE-03 study of Trodelvy plus pembrolizumab in previously untreated metastatic non-small cell lung cancer, the company determined no future cash flows were expected from the lung intangible and wrote the entire remaining balance to zero. The asset came from the $21B Immunomedics acquisition that brought Trodelvy into the company.

The discontinuation appears as a bullet in the press release's list of quarterly updates. The impairment appears on the face of the income statement. Neither was mentioned in prepared remarks, and no analyst raised it during the question period. The strings "impairment," "EVOKE-03" and "write-down" do not appear anywhere in the call.

The lung ambition has not disappeared so much as changed vehicles. The chief medical officer spent part of the question period discussing the potential of GS-8824, the NaPi2b-directed antibody-drug conjugate acquired with Tubulis, in exactly the non-squamous non-small cell lung setting Trodelvy just vacated.

Assessment: A full write-off of a lung indication acquired in Gilead's largest-ever deal is a real reduction in the Trodelvy total addressable market, and it should not have taken a filing footnote to surface it. It is not a cash event and it does not change 2026 earnings power, but it is a data point on how the acquired-pipeline strategy converts, and it lands in the same quarter management is asking investors to look through $11.2B of fresh acquired IPR&D.

7. Revenue up, earnings flat: where the raise went

Base-business guidance rose roughly $350M at the midpoint, and the full-year illustrative earnings range moved from $8.45–$8.85 to $8.50–$8.85. That is five cents on the bottom end and nothing on the top.

"our full year non-GAAP diluted EPS would be $8.50 to $8.85, raised $0.05 on the bottom end from our May illustrative guidance due to higher base sales, partially offset by lower Veklury sales." — Andrew Dickinson, Chief Financial Officer

The CFO named the offset himself. Veklury was halved from approximately $600M to approximately $300M, and that is high-margin revenue disappearing. The second offset is visible in the cost lines: non-GAAP SG&A grew 12% in the quarter against a mid-single-digit full-year framework, on Yeztugo promotional spend.

Assessment: This is the cleanest explanation for why a genuine beat closed down. Investors were shown better demand and unchanged earnings power, and demand you cannot bank is worth less than demand you can. It does not break the thesis, since a $0.05 raise is still a raise and the in-quarter leverage was strong, but it is the reason we are holding conviction rather than raising it.

8. Underlying margins are better than they have been

The reported margin picture is unreadable: GAAP operating margin was negative 133.2% and non-GAAP operating margin negative 93.9%, both entirely the product of expensing the acquisitions. Management supplied the comparable figure.

"Excluding the $11.1 billion in acquired IP R&D expenses associated with the 3 acquisitions, our second quarter operating margin was approximately 49%. This is consistent with the strong margins we've delivered in prior quarters and firmly in the top quartile of our peer group, underscoring our disciplined operating model." — Andrew Dickinson, Chief Financial Officer

Roughly 49% compares with 47% in Q1 and 46.5% reported in the year-ago quarter, achieved while integrating three acquisitions and running four launches.

Assessment: Absorbing three integrations and a 12% step-up in promotional spend while expanding the underlying operating margin is the earnings-quality signature that justifies paying a market multiple for a mid-single-digit revenue grower. It also validates the ex-transaction earnings frame the market keeps declining to use.

9. Cash generation accelerates as the balance sheet thins

Free cash flow was $3,432M in the quarter against $720M a year ago, and $5,859M in the first half against $2,373M. Gilead returned about $1.36B in the quarter through $1.0B of dividends and $355M of buyback, and about $2.87B across the first half, which management put at roughly 49% of first-half free cash flow. It declared a $0.82 quarterly dividend for Q3.

The balance sheet moved the other way. Cash and marketable debt securities fell to $3,179M from $10,605M at year end, on $11.3B of acquisition outflows and $2.8B of debt repayment, partly funded by $4.1B of new debt through a $3.0B senior notes issue and a $1.1B one-year term loan. Stockholders' equity nearly halved to $11,744M from $22,618M.

Assessment: Operating cash generation is not the concern and in fact accelerated sharply. The concern is optionality. A company holding $3.2B of cash against roughly $24B of carrying-value notes has materially less room to respond to a competitive surprise or a bolt-on than it had six months ago, and it is leaning on a one-year term loan to bridge the gap.

10. The acquisition window closes

After roughly $11.5B of deals across three transactions in the first half, management moved from the hedged language of last quarter to something firmer.

"we do not currently anticipate pursuing additional sizable M&A transactions this year. That said, we will remain opportunistic and continue to assess strategic opportunities to further enhance our portfolio and create value." — Andrew Dickinson, Chief Financial Officer

In May the same message was delivered as "less likely." The near-term stated priority is integrating the acquired programs and platforms.

Assessment: The right call, and firmer than we expected. It caps the acquired-IPR&D charge at the $11.5B now guided, gives the market a clean 2027 comparison, and shifts the burden of proof to execution. Given the balance sheet described above, it is also close to a necessity.

11. Diversification: real in the pipeline, not yet in the revenue

Pipeline breadth expanded again, to 53 ongoing clinical programs from 47 last quarter, with the Tubulis ADC platform and the Ouro Medicines T-cell engager closing in the period alongside full ownership of anito-cel through Arcellx. Management was pressed directly on whether reducing HIV concentration remains a goal.

The honest arithmetic is that HIV was 75% of product sales in the quarter, and total oncology grew 3%. Diversification is advancing quickly in programs and slowly in dollars.

Assessment: The acquisitions genuinely deepen the 2028-and-beyond pipeline and the inflammation portfolio is about to get its first real data. But an investor buying Gilead today is still buying an HIV company with options attached, and should size the position accordingly rather than on the diversification narrative.

Guidance & Outlook

This is the second consecutive quarter in which the operating guide improved and the GAAP guide deteriorated, and the two moved for entirely unrelated reasons. Base business, HIV growth and non-GAAP operating income all went up on demand. GAAP operating income and GAAP EPS went down because of the $1.75B lung write-off. Reported non-GAAP EPS improved by $0.40 at the bottom of the range and $0.35 at the top, but $0.35 of that is simply a smaller transaction charge rather than better operations: the per-share impact embedded in the guide fell from $9.50 in May to $9.15 now. That leaves five cents of genuine improvement at the low end and none at the high end, which is exactly what the illustrative range shows.

Implied second-half ramp: First-half product sales of $14,574M against a full-year range of $30.1B–$30.4B implies second-half sales of roughly $15.5B–$15.8B, a 6.5% to 8.6% step up from the first half. Within that, HIV grew 11% in the first half against a full-year guide of 9%–10%, so the guide implies HIV growth decelerating in the second half. Yeztugo needs roughly $600M against $397M booked in the first half. Veklury needs only about $133M against $167M already recorded.

Street at: The total product sales midpoint of roughly $30.25B sits about 0.6% below where the Street was carrying the full year. The base-business raise was not large enough to offset halving Veklury, so the headline guide reads as a small trim even though the underlying business was raised.

Guidance style: Consistent with Gilead's pattern of guiding to a floor and raising into it. HIV growth has now gone from 6% to 8% to 9%–10% across two quarters, and base-business revenue is $750M above the initial February framing at the midpoint. The offsetting habit, equally consistent, is that the earnings guide moves far less than the revenue guide.

Analyst Q&A Highlights

The gap between reported Yeztugo sales and third-party prescription data

The first question of the call went straight at a discrepancy that has been building for months: syndicated prescription trackers have been showing something different from what Gilead reports. Management declined to engage with the reconciliation at all, stating that a year into launch it would no longer comment on how the third-party data is captured.

Q: "can you help us better understand the growing delta in recent Yeztugo prescription trends versus sales that are being reported by outlets like IQVIA?"
— Tyler Van Buren, TD Cowen

A: "now that we're about a year into the launch, we won't be commenting on how IQVIA captures the data. We'll obviously be commenting on our data, which has all the pieces of the puzzle pulled in together."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: A refusal to reconcile is a defensible position for a company with better data than the trackers, and gross-to-net and channel effects genuinely do distort scripts-to-sales for a buy-and-bill injectable. It also removes the only external check investors had on the launch trajectory. With the guide flat at $1B and the second half requiring a further step up, that check mattered more this quarter than last.

Why fund an oral prevention option when the injectable was the value proposition

A sharp strategic challenge questioned whether investing behind a once-weekly oral undercuts the premise of a twice-yearly injectable, and whether it signalled softer-than-expected enthusiasm for long-acting dosing. Management rejected the premise and reframed the oral as market expansion rather than substitution.

Q: "The value proposition for Yeztugo was built around eliminating the need to multiple pills every week. Yet now you're investing behind a once-weekly oral PrEP option, which yes, is better than Descovy. I'm curious as to what has changed. Are you seeing that people just aren't as enthusiastic about a twice yearly injection as you originally thought?"
— Evan Seigerman, BMO Capital Markets

A: "I would say nothing has changed. On the contrary, I think what we're seeing is incredible excitement for the long-acting. We've always suggested that we felt that long-acting options longer with better in a PrEP setting, especially. What we do know, however, is that you still have about 80%, 85% of the total market that are daily orals, both Descovy as well as generic TDF. And so there is still a huge opportunity."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: The answer is right on the arithmetic. If 80% to 85% of the market still takes a daily pill, a weekly pill addresses a far larger pool than an injectable will reach in this decade. The portfolio logic holds, and the persistency data disclosed on the same call undercuts the premise that injectable enthusiasm is fading.

Whether the 70% persistency rate can be pushed higher

Having volunteered the persistency figure, management was immediately asked what levers exist to improve it and what could cause it to deteriorate. The answer was operational and specific, describing a patient support program launched within the prior month.

Q: "you mentioned there's a 70% compliance. How are you thinking about things that you could do to get it higher? Are there things that you're seeing in the channel and in the marketplace and patient feedback? And what are the factors that could consider making it lower?"
— Michael Yee, UBS

A: "Over 70% is definitely by far the strongest persistency rate that we've seen across all the options in PrEP. And to your point, of course, the team is trying to make sure that we continue to challenge ourselves. We've done a lot of programs already at the HCP level to make sure that the right reminders, leveraging the EMR system, the EHR system to make sure that they're part and parcel of your logistics. The team has just recently launched in the last month or so, a support program for individuals on PrEP. It's actually called Ready to Go."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: Management answered the upside half of the question in detail and skipped the downside half entirely. What could make persistency deteriorate was asked and never addressed. The commercial infrastructure described is substantive, but the asymmetry in the answer is worth noting given the figure is one data point at one time horizon.

Biktarvy strength set against U.S. insurance coverage losses

The most useful exchange of the call pressed on the apparent contradiction between above-consensus Biktarvy sales and known insurance coverage losses, asking specifically how to separate volume dynamics from mix and pricing. The response conceded the demand impact more directly than the prepared remarks had.

Q: "I really wanted to just understand a little bit more about the HIV treatment strength specifically kind of looking at Biktarvy, we saw performance beyond consensus expectations. And this is in the context of insurance coverage losses in the U.S. And so wanting to get your context around how we should think about the drivers of those different volume dynamics relative to the mix and other pricing dynamics that are playing out for a product like Biktarvy."
— Courtney Breen, Bernstein

A: "with the ACA tax subsidies being eliminated, there's some folks that have basically fallen out of insurance plans, right? So most of those are health exchange plans where the patients are actually either now become uninsured or underinsured, and they're kind of navigating the channels to understand where they go next. And so there's a little bit of a transition. And so we kind of saw that directly impact the HIV treatment market. So it was a little softer in Q2. We believe that will bounce back to the 2% to 3% that we've seen in the past and that we expect to see in the future."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: This is the exchange that explains the stock's reaction better than the guidance table does. A quarter in which the reported number beats while the underlying market softens is a quarter carried by price and stocking, and management confirmed as much when pushed. The recovery to 2%–3% was asserted without evidence or timing, which leaves the largest franchise in the company resting on an unverified assumption.

Descovy pricing durability and cannibalization from the weekly oral

A two-part question probed whether the first-half price benefit in Descovy can persist through the rest of the year, and whether next year's weekly oral will cannibalize it more aggressively than the injectable has. Management defended durability "to a point" and characterized the weekly oral as an opportunity to convert generics as much as Descovy.

Q: "as we think about the rest of the year, should we think about this level of year-over-year price benefit we've seen in the first half of the year continuing? And then as we look forward on Descovy and with the weekly Yeztugo coming to market next year, do you see weekly Yeztugo as a product that can more meaningfully cannibalize Descovy?"
— Christopher Schott, JPMorgan

A: "On Descovy, we have been seeing really nice growth, right, 60% year-over-year. […] we do believe the Qweekly oral is going to be a really nice opportunity for both Descovy, but also for generics to move over to the Qweekly Yeztugo option."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: The qualifier "to a point" is the tell. Management is signalling that the channel-mix price benefit running through Descovy has a finite life, which matters because that benefit is a meaningful part of the HIV guide raise. Cannibalization is the lesser worry: converting a generic user to a branded weekly is accretive regardless of what it does to Descovy.

Whether reducing HIV concentration is still a strategic objective

A bigger-picture question observed that the pipeline has diversified but the revenue base has not, and asked whether lowering HIV concentration remains an intentional goal or has quietly been deprioritized. Management reaffirmed the objective and redefined it as running along two axes rather than one.

Q: "you guys have clearly diversified the business today in terms of pipeline, but you're not really there yet with respect to sales. You guys used to talk about this a lot, but is lowering the concentration of HIV still an intentional long-term goal at Gilead? Or has that become less of a priority as long as you just have strong growth, cash flow, improving margins, et cetera?"
— Geoffrey Meacham, Citibank

A: "Clearly, our objective is still to diversify the business, but in 2 different ways, just to clarify. One is within virology and the second one is outside of virology."
— Daniel O'Day, Chairman & CEO

Assessment: Redefining diversification to include diversification within HIV is a meaningful softening of a goal that used to mean reducing HIV as a share of revenue. It is not unreasonable, since a portfolio of daily, weekly, monthly and twice-yearly options genuinely spreads risk. But investors who took the original framing at face value should register that the target moved.

Regulatory requirements for anito-cel in earlier lines

With the second-line study fully enrolled and a filing possible as early as next year, questioning turned to whether shifting FDA leadership and evolving positions on CAR-T registrational requirements have changed what will be needed. The response was that interactions have been unremarkable and the dual primary endpoint remains the filing basis.

Q: "I'm just curious how consistent your regulatory interactions have been at least in the lead line and maybe your latest impressions of what the filing requirements might be for the earlier second line to fourth-line patients."
— Brian Abrahams, RBC Capital Markets

A: "we continue to have interactions with the FDA as part of normal course of business and questions during a filing and have not seen major changes at this point. I think the components that you're referencing on the earlier lines of therapy, again, we have a dual primary endpoint of both minimal residual disease and PFS and are continuing to progress those endpoints and would plan to file based on the dual primary with FDA and haven't had any conversations that would indicate differently."
— Cindy Perettie, Executive Vice President, Kite

Assessment: A clean, unhedged answer on the question that most affects how fast cell therapy can return to growth. Minimal residual disease as a co-primary endpoint is the accelerant, since it reads out far earlier than progression-free survival. The commitment that no conversation has suggested otherwise is the most specific regulatory reassurance offered on the call.

What They're NOT Saying

1. The $1.75B write-off: The full impairment of the Trodelvy lung intangible was disclosed on the income statement and explained in the quarterly filing, but never raised in prepared remarks and never asked about in the question period. A charge of this size arising from a discontinued Phase 3 study is exactly the kind of item a call is for.
2. The size of the ACA impact: Management called the effect on the HIV treatment market "greater-than-expected" and offered no quantification, no split between lost patients and deferred starts, and no timeline for the asserted recovery to 2%–3% growth.
3. The volume-versus-price split in HIV: Biktarvy's growth was attributed to price, inventory and demand, and Descovy's to price and demand, with no figure attached to any of the three. Given that the guide raise rests on these two products, this is the most consequential omission in the release.
4. Why Yeztugo was not raised: The HIV franchise guide went up while the fastest-growing product in it stayed at approximately $1B. Nobody explained whether that reflects conservatism or an expected flattening of the launch curve.
5. What changed in cell therapy: The full-year decline guide worsened from roughly 10% to mid-teens inside a guidance walk, with no discussion of which product, which geography, or which competitor drove the revision.
6. Reconciliation to third-party prescription data: Management explicitly withdrew from commenting on the growing gap between syndicated prescription trends and reported Yeztugo sales, removing the only independent read on the launch.
7. Balance-sheet plans: Cash fell to $3.2B and equity nearly halved, funded in part by a one-year term loan, and the call contained no discussion of the leverage path, refinancing intentions, or what the reduced cash position means for buyback capacity beyond the current pace.

Market Reaction

• Pre-print setup: Gilead closed at $135.25 on August 4 ahead of the after-market release, up 10.2% year to date against 13.0% for the S&P 500, up 18.1% over the trailing twelve months and 3.0% over the trailing thirty days. The 52-week closing range entering the print was $110.28 to $155.80, leaving the stock roughly 13% below its record close.
• Reaction session: Shares gapped up 0.6% to open at $136.00 on August 5, traded as high as $137.80 and as low as $129.60, and closed at $131.76, down 2.6% or $3.49. The S&P 500 fell 0.2% the same session.
• Volume: 11.4 million shares against a 30-day average of 7.3 million, roughly 1.6 times normal.
• Intraday pattern: The full peak-to-trough range spanned 6.0% of the pre-print close, with the open above the prior close and the close near the low of the day.

The shape of the session is more informative than the magnitude. The stock opened higher, which is what a top- and bottom-line beat with a raised HIV guide should produce, then sold off through the day to close near its low. That pattern is the market working through the guidance table rather than reacting to the headline, and there are three things in that table to work through.

The first is that the total product sales midpoint of roughly $30.25B came in slightly below where consensus sat, because halving Veklury to approximately $300M consumed more than the $350M base-business raise added. A company can raise the part of the business investors care about and still deliver a headline guide that reads as a trim. The second is the earnings conversion. A $350M revenue raise that produces five cents of illustrative EPS on the low end and nothing on the high end tells investors the incremental revenue is arriving with an offsetting cost, and the 12% growth in non-GAAP SG&A shows where. The third is the cell therapy cut, which lands squarely on the 2026 earnings bridge with the anito-cel recovery not arriving until 2027.

What the market did not appear to price at all is the $1.75B write-off, which is consistent with management never having raised it and no analyst having asked. Volume at 1.6 times normal on a 2.6% decline is position adjustment rather than a thesis break: this is a set of investors trimming on a guide that did not improve their model, not exiting on a broken story.

Street Perspective

Debate: Is the HIV acceleration demand or price?

Bull view: The prevention business doubled year over year and crossed $1B in a quarter, inside a U.S. PrEP market growing 14%, with a six-month persistency rate above 70% confirming users stay. That is volume, in a market that is itself expanding, and it supports a franchise growth rate that has now been raised twice in six months.

Bear view: The company's own release leads with realized price on both Biktarvy and Descovy, adds favorable inventory dynamics on Biktarvy, and management conceded the underlying HIV treatment market softened on the ACA subsidy expiry. Price and channel mix are finite and inventory reverses, so a meaningful part of the raise is not repeatable.

Our take: Both are right about different halves of the franchise. Prevention growth is overwhelmingly volume and is the highest-quality growth in the company. Treatment growth this quarter was substantially price, mix and stocking against a softening market. Since treatment is still much the larger pool, the blended growth rate is lower quality than the headline implies, and the honest position is to credit the raise while widening the uncertainty band around 2027.

Debate: Did the acquisition wave buy growth or just leverage?

Bull view: Roughly $11.5B bought full ownership of a best-in-class myeloma cell therapy five months from a decision, a next-generation ADC platform with a lead asset showing a 61% response rate in platinum-resistant ovarian cancer, and an entry into inflammation. The pipeline went from 47 programs to 53, the charge is non-cash, and management has now closed the acquisition window to focus on integration.

Bear view: Cash fell from $10.6B to $3.2B, equity nearly halved, a one-year term loan is helping bridge the gap, and the first write-off already landed in the same quarter, on an asset from the largest deal the company ever did. Buying pipeline is easy and converting it is not, and the conversion record now includes a full impairment.

Our take: The bull case is better on the assets and the bear case is better on the timing. These are defensible deals struck from a position of strength with no patent cliff forcing the issue, which is the right time to buy. But the balance sheet has materially less give than it did in January, and the lung write-off is a reminder that acquired intangibles carry both directions. The M&A pause is the correct response and the reason we are not marking this bear point higher.

Debate: Is 15x ex-transaction earnings cheap or fair?

Bull view: A business with no major exclusivity loss until 2036, an underlying operating margin near 49%, first-half free cash flow of $5.9B, an accelerating prevention franchise and four launches in a single year should not trade at a mid-teens multiple. The Street's average target sits roughly 19% above the current price.

Bear view: Revenue growth is mid-single-digit on a full-year basis, the earnings guide barely moved despite the revenue raise, cell therapy is deteriorating faster than planned, and reported GAAP and non-GAAP results will show losses all year. Mid-teens is the correct multiple for a mid-single-digit grower with policy exposure.

Our take: The bear description of the growth rate is accurate and the bull description of the quality is also accurate, and quality is what mid-teens does not currently pay for. At $131.76 the stock trades at roughly 15x the midpoint of management's illustrative $8.50–$8.85, essentially the same multiple we upgraded into in May at $131.33, except the base-business guide is $350M higher, HIV growth is one to two points higher, and the largest unknown in the thesis has been resolved favorably. Paying an unchanged multiple for a demonstrably better-understood business is the argument for staying long.

Model Update Needed

Valuation impact: No change to our framework. The illustrative earnings range moved five cents, which is immaterial. What changed is the confidence interval rather than the point estimate: the persistency disclosure narrows the distribution of outcomes for the prevention franchise, while the ACA disclosure widens it for treatment. At $131.76 the stock trades at roughly 15x the midpoint of the illustrative range, and the Street's average twelve-month target of about $157 sits roughly 19% above the reaction-day close.

Thesis Scorecard Post-Earnings

Overall: Strengthened, modestly. The most important pillar improved on both the guide and the disclosure that mattered most, and the persistency figure removes the largest genuine unknown we have carried since initiation. Working the other way, the policy bear escalated from contained to emerging on management's own characterization, and the cell therapy guide deteriorated. The net is a better-understood business at an unchanged multiple.

Action: Hold the position and stay long. We are maintaining Outperform and holding conviction at 7 rather than raising it, and the reason is specific: a $350M revenue raise that produces five cents of earnings is not yet the operating leverage the long case ultimately requires. The next three checkpoints are the August 27 BIC/LEN decision, whether the HIV treatment market returns to 2%–3% growth as asserted, and whether the second-half Yeztugo ramp to roughly $300M a quarter materialises.